相关临床试验
0
0 进行中
药物批准
482
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Teva Pharmaceuticals and the Trump Administration announced a shared commitment to lower the cost of select medicines for American patients covered by Medicaid. - If finalized, the agreement would align U.S. Medicaid pricing for select medicines with leading developed markets through the GENEROUS framework. - The deal would include a prospective Most-Favored-Nation (MFN) commitment for future innovative product launches and a dedicated reserve of certain active pharmaceutical ingredients (API). - Teva says the agreement would support continued investment in scientific innovation and U.S. pharmaceutical manufacturing capabilities.
- Teva Pharmaceuticals has asked a Philadelphia federal court to prevent Humana from identifying it as an Israeli company during an upcoming price-fixing trial, arguing the Gaza war has created widespread anti-Israel sentiment that could prejudice jurors. - The trial, scheduled to begin September 15, involves allegations that Teva and other drug makers conspired to inflate prices of generic drugs including baclofen and propranolol. - Teva cited polling showing 60% of Americans hold a negative view of Israel and pointed to campus protests and acts of violence against Israel-affiliated entities as evidence of potential juror bias. - Humana separately requested the court bar defendants from introducing inflammatory evidence about health insurers, referencing the 2024 killing of UnitedHealthcare's CEO.
- Three University of South Carolina College of Pharmacy students completed transformative summer internships spanning Capitol Hill advocacy, corporate retail pharmacy, and pharmaceutical marketing. - Sun Heslin served as the Carl F. Emswiller Summer Intern at the American Pharmacists Association, advocating for the Mainstreet Pharmacy Access Act, ECAPS, and the PrEP Access Act in congressional offices. - Max Swink interned at Publix Pharmacy headquarters, gaining exposure to business strategy, regulatory compliance, and corporate leadership, while Carli Muniz completed Teva Pharmaceuticals' Innovative Medicines Marketing Internship. - The experiences reinforced students' interest in pharmacy leadership and broadened their understanding of how pharmacists can contribute to patient care and the profession.
- Nevada Attorney General Aaron Ford and a coalition of 43 states announced a $400 million settlement in principle with Sandoz Inc. over allegations of widespread generic drug price manipulation. - The settlement resolves claims that Sandoz and its international affiliates engaged in long-running conspiracies to artificially inflate prices and reduce competition on numerous generic prescription drugs. - Sandoz has agreed to injunctive terms including internal reforms to ensure fair competition and compliance with antitrust laws, with a trial anticipated in 2027. - The broader multistate antitrust litigation, ongoing since 2016, has now secured settlements totaling approximately $565.5 million across multiple generic drug manufacturers.
- Clinical research site performance is driven more by operating model than by traditional metrics like site count, investigator numbers, or therapeutic area coverage. - Freestanding research clinics offer strong operational control and faster start-up, with median activation of 4.37 months versus 8.12 months for academic medical centers. - Embedded private-practice sites provide superior patient access through treating physician relationships, while contracted PIs can create bottlenecks without adequate operating support. - A centrally governed hybrid model combining freestanding clinics with embedded private-practice operations may offer the optimal balance of access, control, speed, quality, and scalability.
- The phase 3 SOLARIS trial found subcutaneous long-acting injectable olanzapine (TV-44749) significantly improved symptom severity across all three dose groups in patients with schizophrenia. - No confirmed cases of postinjection delirium/sedation syndrome (PDSS) were reported among more than 600 patients and approximately 3,600 injections administered. - The existing intramuscular olanzapine LAI carries a well-documented risk of PDSS, making this subcutaneous formulation a potentially safer alternative if approved. - If approved, TV-44749 could expand LAI utilization in a population where medication adherence remains a persistent clinical barrier.
- UroGen Pharma Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares for $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan. - The sale occurred with UroGen's market capitalization at $2.0 billion and shares priced at $40.23, following a 191.31% one-year stock appreciation. - Schoenberg retains 119,763 ordinary shares directly following the transaction, which represents the concluding trade of the August 2025 trading plan schedule. - The company reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million, with Zusduri and Jelmyto driving commercial performance.
- The generic drug industry is shifting from traditional small-molecule generics toward biosimilars, complex generics, and specialty injectables as price erosion pressures margins on commodity generics. - Sandoz reported Q1 2026 net sales of $2.76 billion with biosimilars growing 18% year-over-year, now accounting for nearly one-third of total revenues. - Teva, the world's largest generic drugmaker, expects its biosimilars business to generate $800 million in revenues by 2027, supported by its strategic partnership with Alvotech. - The Zacks Medical–Generic Drugs industry has surged approximately 44% over the past year, outperforming both the broader Zacks Medical sector and the S&P 500 Index.
- A first-of-its-kind real-world, decentralized study reveals that over 68% of Huntington's disease chorea patients report interference with social life or emotional wellbeing, with up to 83% of caregivers noting impact on their own daily lives. - Following treatment with AUSTEDO or AUSTEDO XR, 74% of patients reported improvements in chorea movements on the PGIC scale, and over 85% reported improvements in daily activity and social life goals. - 77% of caregivers reported improvements in goals related to their own social life and emotional wellbeing, including reduced guilt, stress, and emotional burden, as a result of the patient's reduced chorea. - The findings, presented at the Advanced Therapeutics in Movement & Related Disorders Congress, reinforce the importance of effective chorea management in preserving patient independence and alleviating caregiver strain.
- UroGen Pharma has reached a settlement agreement with Teva Pharmaceuticals that resolves patent litigation over JELMYTO, granting Teva a non-exclusive license to sell its generic version beginning September 15, 2030. - The agreement preserves nearly all of UroGen's patent protection period for JELMYTO, which has regulatory exclusivity through April 2027 and Orange Book-listed patents expiring January 20, 2031. - JELMYTO is approved for treating low-grade upper tract urothelial cancer using UroGen's proprietary RTGel reverse-thermal hydrogel technology that enables sustained drug release. - The settlement reinforces the value of UroGen's innovation and intellectual property portfolio while allowing continued execution of their mission to transform uro-oncology treatment paradigms.
